Literature DB >> 8643167

Report on intensive treatment of extracapillary glomerulonephritis with focus on crescentic IgA nephropathy.

D Roccatello1, M Ferro, R Coppo, G Giraudo, G Quattrocchio, G Piccoli.   

Abstract

UNLABELLED: PURPOSE AND DESIGN OF STUDY: In this retrospective analysis the effects of combined treatment with steroid pulses, cyclophosphamide and plasma exchange on six crescentic IgA glomerulonephritis (IgAGN) patients, selected on a histological basis, were examined. The histological criteria included involvement of more than 40% of glomeruli by cellular crescents. The effects of this treatment were compared to those observed in three untreated crescentic IgAGN patients and 12 treated patients who had extracapillary glomerulonephritis of different origins, i.e. ANCA-associated systemic or renal-limited vasculitis. All patients, except the three crescentic untreated IgAGN patients, received the same 2-month treatment according to a standardized protocol: steroid boli 15 mg/kg methylprednisolone for 3 consecutive days by intravenous infusion, followed by prednisone per os (1 mg/kg/day for 4 weeks, 0.75 mg/kg/day for 4 more weeks), cyclophosphamide per os 2.5 mg/kg/day for 8 weeks, and plasma exchange.
RESULTS: After this 2-month course of therapy, substantial clinical improvement was observed in both IgAGN and vasculitis patients. However, a second biopsy revealed that florid crescents persisted in IgAGN patients and, unlike the vasculitis group, during the long-term the initial clinical amelioration disappeared in one-half of the treated IgAGN cases. Nevertheless, even in the progressive cases, intensive treatment seemed to substantially delay the onset of dialysis.
CONCLUSIONS: Despite some clinical benefits of therapy, short-term reversal of active crescents appears less likely to occur in crescentic IgAGN than in vasculitis-associated crescentic GN. Intensive treatment seems sufficient to arrest, but inadequate to reverse, phlogistic lesions in IgAGN before development of chronic changes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8643167

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  7 in total

1.  The difficulty in considering modifiable pathology risk factors in children with IgA nephropathy: crescents and timing of renal biopsy.

Authors:  Rosanna Coppo; Jean-Claude Davin
Journal:  Pediatr Nephrol       Date:  2014-10-16       Impact factor: 3.714

2.  Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation.

Authors:  Xia-Hong Shen; Shao-Shan Liang; Hui-Mei Chen; Wei-Bo Le; Song Jiang; Cai-Hong Zeng; Min-Lin Zhou; Hai-Tao Zhang; Zhi-Hong Liu
Journal:  J Nephrol       Date:  2015-01-14       Impact factor: 3.902

Review 3.  Rituximab therapy for IgA-vasculitis with nephritis: a case series and review of the literature.

Authors:  Roberta Fenoglio; Carla Naretto; Bruno Basolo; Giacomo Quattrocchio; Michela Ferro; Paola Mesiano; Giulietta Beltrame; Dario Roccatello
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

4.  In crescentic IgA nephropathy, fractional excretion of IgG in combination with nephron loss is the best predictor of progression and responsiveness to immunosuppression.

Authors:  Claudio Bazzi; Virginia Rizza; Sara Raimondi; Daniela Casellato; Pietro Napodano; Giuseppe D'Amico
Journal:  Clin J Am Soc Nephrol       Date:  2009-04-30       Impact factor: 8.237

5.  Complete remission of nephrotic syndrome and acute kidney injury in crescentic IgA nephropathy: Role of mycophenolate sodium.

Authors:  D Bhandari; K D Jhaveri; H H Shah
Journal:  Indian J Nephrol       Date:  2016-09

6.  IgA nephropathy in Greece: data from the registry of the Hellenic Society of Nephrology.

Authors:  Maria Stangou; Marios Papasotiriou; Dimitrios Xydakis; Theodora Oikonomaki; Smaragdi Marinaki; Synodi Zerbala; Constantinos Stylianou; Pantelitsa Kalliakmani; Aimilios Andrikos; Antonia Papadaki; Olga Balafa; Spyridon Golfinopoulos; Georgios Visvardis; Georgios Moustakas; Evangelos Papachristou; Theodora Kouloukourgiotou; Eleni Kapsia; Angeliki Panagiotou; Constantinos Koulousios; Christos Kavlakoudis; Maria Georgopoulou; Stylianos Panagoutsos; Demetrios V Vlahakos; Theophanis Apostolou; Ioannis Stefanidis; Kostas Siamopoulos; Ioannis Tzanakis; Apostolos Papadogiannakis; Eugene Daphnis; Christos Iatrou; John N Boletis; Aikaterini Papagianni; Dimitrios S Goumenos
Journal:  Clin Kidney J       Date:  2017-07-31

7.  Immunosuppressive Treatment in Children With IgA Nephropathy and the Clinical Value of Podocytopathic Features.

Authors:  Alexandra Cambier; Marion Rabant; Michel Peuchmaur; Alexandre Hertig; Georges Deschenes; Cecile Couchoud; Anne Kolko; Remi Salomon; Julien Hogan; Thomas Robert
Journal:  Kidney Int Rep       Date:  2018-03-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.